New possibilities in the pharmacologic prevention of age-related macular degeneration

Orvosi hetilap
Tamás Fischer

Abstract

The beneficial effect achieved by the treatment of endothelial dysfunction in chronic cardiovascular diseases is already an evidence belonging to the basic treatment of the disease. Given the fact that the vascular system is uniform and consubstantial both physiologically, pathophysiologically and in terms of therapy, and that it plays a key role in age-related macular degeneration (AMD)--a disease leading to tragic loss of vision with its etiology and therapy being unknown--endothelial dysfunction should be treated. The pleiotropic effects of ACE-inhibitors, AR-blockers and statins help to restitute the balance between vasodilators and vasoconstrictors in endothelial dysfunction caused by oxidative stress, the balance of growth factors and their inhibitors, pro- and anti-inflammatory substances and prothrombotic and fibrinolytic factors, inhibit the formation of oxidative stress and its harmful effects; while aspirin with its pleiotropic effects acting as an antiaggregation substance on platelets helps to set the endothelial layer back to its normal balance regarding its vasodilating, antithrombotic, antiadhesive and anti-inflammatory functions; trimetazidine as an adjuvant agent helps to normalize, to restore the disturbed me...Continue Reading

References

Aug 15, 1995·American Journal of Epidemiology·J R VingerlingP T de Jong
May 1, 1997·Cardiovascular Research·G Y Lip, A Blann
Apr 30, 1998·Physiological Reviews·K B Beckman, B N Ames
Jul 27, 1999·Ophthalmic Epidemiology·K K Snow, J M Seddon
Aug 12, 1999·European Journal of Pharmacology·D A GreeneE L Feldman
May 8, 2000·Zeitschrift für Kardiologie·B F BeckerS Zahler
Oct 18, 2000·Survey of Ophthalmology·S BeattyM Boulton
Apr 5, 2001·Progress in Retinal and Eye Research·P L PenfoldJ M Provis
Aug 18, 2001·BMJ : British Medical Journal·N F HallC N Martyn
Jun 1, 2002·Journal of the American Society of Nephrology : JASN·Wulf Palinski, Sotirios Tsimikas
Nov 1, 2002·Klinische Monatsblätter für Augenheilkunde·Albert J AugustinUrsula Schmidt-Erfurth
Aug 21, 2003·The British Journal of Ophthalmology·G McGwinR J Crain
Sep 6, 2003·Journal of the American College of Cardiology·Kwang Kon KohEak Kyun Shin
Oct 3, 2003·Journal of the American College of Cardiology·Michael E WidlanskyJoseph A Vita
Dec 5, 2003·Archives of Biochemistry and Biophysics·Marco ValgimigliRoberto Ferrari
Jan 23, 2004·Journal of the American College of Cardiology·Melvin D Cheitlin
Feb 12, 2004·JAMA : the Journal of the American Medical Association·Johanna M SeddonNader Rifai
Jul 6, 2004·Ophthalmology·Sandra C TomanyPaulus T V M De Jong
Aug 11, 2004·European Heart Journal·José López-SendónUNKNOWN Task Force on ACE-inhibitors of the European Society of Cardiology
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Mar 29, 2005·Vascular Pharmacology·Folkert W AsselbergsWiek H van Gilst
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·James K Liao, Ulrich Laufs
Apr 20, 2005·Journal of the American College of Cardiology·Rainer Schulz
Apr 20, 2005·Regulatory Peptides·Nidia BassoFelipe Inserra
Aug 2, 2005·International Journal of Cardiology·Khalid AlmutiRobert J Ostfeld
Oct 18, 2005·Journal of the American College of Cardiology·Kausik K Ray, Christopher P Cannon
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Subodh VermaPaul M Ridker
Feb 18, 2006·Klinische Monatsblätter für Augenheilkunde·Tamás Fischer
Jul 20, 2006·JAMA : the Journal of the American Medical Association·Dominiek D G DesprietPaulus T V M de Jong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.